Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+2.88%
$0.72
0% positive prob.
5-Day Prediction
-3.90%
$0.67
0% positive prob.
20-Day Prediction
-37.66%
$0.44
0% positive prob.
SEC 8-K filings with transcript text
Nov 17, 2025 · 100% conf.
1D
+2.88%
$0.72
Act: +0.00%
5D
-3.90%
$0.67
Act: -1.59%
20D
-37.66%
$0.44
Act: -28.30%
cosm_8k.htm0001474167false00014741672025-11-172025-11-17iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 17, 2025
Cosmos Health Inc.
(Exact name of registrant as specified in its charter)
Nevada
000-54436
27-0611758
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
5 AGIOU GEORGIOU, Pilea, Thessaloniki, Greece
55438
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (312) 865-0026
(Former name or former address, if changed since last report.)
Title of Each Class
Trading Symbol
Name of Each Exchange On Which Registered
Common Stock, $.001 par value
The Nasdaq Stock Market LLC
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On November 17, 2025, Cosmos Health Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the quarter and nine months ended September 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference in this Item 2.02.
The information set forth in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.
In accordance with General Instruction B.2 to Form 8-K, the information set forth in the Items 2.02 and 7.01 and in Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in that filing.
By furnishing this Current Report on Form 8-K, the Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including the statements made in Items 2.02 and 7.01 above and in Exhibit 99.1 hereto.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release issued by Cosmos Health Inc., dated November 17, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 17, 2025 By: /s/ Georgios Terzis
Georgios Terzis
Chief Financial Officer
3
Nov 22, 2023
cosm_8k.htm0001474167false00014741672023-11-212023-11-21iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 21, 2023
(Exact name of registrant as specified in its charter)
Nevada
000-54436
27-0611758
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
5 Agiou Georgiou Str, Pilea, Thessaloniki, Greece
55438
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (312) 536-3102
N/A (Former name or former address, if changed since last report.)
Title of Each Class
Trading Symbol
Name of Each Exchange On Which Registered
Common Stock, $.001 par value
Nasdaq Capital Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
A copy of the press release dated November 21, 2023 of Cosmos Health Inc. titled “Cosmos Health Reports Third Quarter 2023 Financial Results” is filed as Exhibit 99.1 to this Report on Form 8-K. The release contains additional non-public information to that contained in the Company’s current report on Form 10-Q filed with the SEC on November 20, 2023.
(d) Exhibits
Number
99.1 Press Release dated November 21, 2023, titled “Cosmos Health Reports Third Quarter 2023 Financial Results”.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 22, 2023 By: /s/ Georgios Terzis
Georgios Terzis
Chief Financial Officer
3
Aug 15, 2023
cosm_8k.htm0001474167false00014741672023-08-152023-08-15iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 15, 2023
Cosmos Health Inc.
(Exact name of registrant as specified in its charter)
Nevada
000-54436
27-0611758
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
141 West Jackson Blvd, Suite 4236, Chicago, Illinois
60604
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (312) 865-0026
N/A (Former name or former address, if changed since last report.)
Title of Each Class
Trading Symbol
Name of Each Exchange On Which Registered
Common Stock, $.001 par value
Nasdaq Capital Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
A copy of the Company’s Press Release dated August 15, 2023 titled: “Cosmos Health Reports Q2 2023 Financial Results; Adjusted Net Income Increases by 3550% to Surpass $3 Million for H1 2023 vs $(0.09) Million H1 2022; Book Value per Share Exceeds $4.04” is filed as Exhibit 99.1 to this Report on Form 8-K.
(d) Exhibits
99.1
Press Release dated August 15, 2023 titled “Cosmos Health Reports Q2 2023 Financial Results; Adjusted Net Income Increases by 3550% to Surpass $3 Million for H1 2023 vs $(0.09) Million H1 2022; Book Value per Share Exceeds $4.04.”
104
Cover Page Interactive Data File (embedded within the Inline XBRL Document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 15, 2023 By: /s/ Georgios Terzis
Georgios Terzis
Chief Financial Officer
3
This page provides Cosmos Health Inc. (COSM) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on COSM's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.